191 related articles for article (PubMed ID: 34110559)
1. Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis.
Strzebonska K; Wasylewski MT; Zaborowska L; Polak M; Slugocka E; Stras J; Blukacz M; Gyawali B; Waligora M
Target Oncol; 2021 Jul; 16(4):415-424. PubMed ID: 34110559
[TBL] [Abstract][Full Text] [Related]
2. Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.
Waligora M; Bala MM; Koperny M; Wasylewski MT; Strzebonska K; Jaeschke RR; Wozniak A; Piasecki J; Sliwka A; Mitus JW; Polak M; Nowis D; Fergusson D; Kimmelman J
PLoS Med; 2018 Feb; 15(2):e1002505. PubMed ID: 29462168
[TBL] [Abstract][Full Text] [Related]
3. Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis.
Strzebonska K; Blukacz M; Wasylewski MT; Polak M; Gyawali B; Waligora M
BMC Med; 2022 Jul; 20(1):219. PubMed ID: 35799149
[TBL] [Abstract][Full Text] [Related]
4. Revisiting Risk and Benefit in Early Oncology Trials in the Era of Precision Medicine: A Systematic Review and Meta-Analysis of Phase I Trials of Targeted Single-Agent Anticancer Therapies.
Mackley MP; Fernandez NR; Fletcher B; Woolcott CG; Fernandez CV
JCO Precis Oncol; 2021 Nov; 5():17-26. PubMed ID: 34994588
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
8. A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.
Dorris K; Liu C; Li D; Hummel TR; Wang X; Perentesis J; Kim MO; Fouladi M
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27654490
[TBL] [Abstract][Full Text] [Related]
9. Communication about the risks and benefits of phase I pediatric oncology trials.
Hazen RA; Zyzanski S; Baker JN; Drotar D; Kodish E
Contemp Clin Trials; 2015 Mar; 41():139-45. PubMed ID: 25638751
[TBL] [Abstract][Full Text] [Related]
10. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
12. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
13. Clinical development success rates and social value of pediatric Phase 1 trials in oncology.
Wasylewski MT; Strzebonska K; Koperny M; Polak M; Kimmelman J; Waligora M
PLoS One; 2020; 15(6):e0234911. PubMed ID: 32579564
[TBL] [Abstract][Full Text] [Related]
14. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.
Goldenberg JZ; Yap C; Lytvyn L; Lo CK; Beardsley J; Mertz D; Johnston BC
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006095. PubMed ID: 29257353
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
17. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
Roberts TG; Goulart BH; Squitieri L; Stallings SC; Halpern EF; Chabner BA; Gazelle GS; Finkelstein SN; Clark JW
JAMA; 2004 Nov; 292(17):2130-40. PubMed ID: 15523074
[TBL] [Abstract][Full Text] [Related]
18. Extended-interval aminoglycoside administration for children: a meta-analysis.
Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
20. Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved.
Zhang SX; Fergusson D; Kimmelman J
J Natl Cancer Inst; 2020 Sep; 112(9):886-892. PubMed ID: 32239146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
